Business Description
Hepion Pharmaceuticals (Nasdaq: HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease – from triggering events through to end-stage disease.
Corporate Presentation
IR Contacts
Investor Relations
Stephen Kilmer
Investor Relations
Phone: 646-274-3580
Email: skilmer@hepionpharma.com
Transfer Agent
Bob Winterle
Philadelphia Stock Transfer
Phone: 866-223-0448
Email: bwinterle@philadelphiastocktransfer.com
Auditor
BDO USA, LLP
100 Park Avenue
New York, NY 10017
Phone: 212-885-8000
U.S. Legal Council
Jeffrey J. Fessler
Sheppard Mullin
30 Rockefeller Plaza
New York, NY 10112
Industry Classifications
Sector
Manufacturing
Industry
Pharmaceutical Preparations
SIC
2834
Frequently Asked Questions
Can I buy stock directly from Hepion?
No, you will need to contact a licensed stock broker or use an online trading account.
How can I buy stock in Hepion?
Through a licensed stock broker or by using an online trading account.
How do I get my purchased shares?
Contact Hepion’s transfer agent Bob Winterle of Philadelphia Stock Transfer at 866-223-0448 or by email at bwinterle@philadelphiastocktransfer.com.
What is Hepion’s CUSIP number?
426897104
Whom can I contact for general information about Hepion?
Contact Stephen Kilmer at skilmer@hepionpharma.com or by phone 646-274-3580.
When was Hepion founded?
Hepion Pharmaceuticals (formerly ContraVir Pharmaceuticals) was spun-off from Synergy Pharmaceuticals in 2014 through a SEC Form 10 filing.
Where is Hepion headquartered?
399 Thornall Street, 1st Floor
Edison, NJ 08837
When is Hepion’s fiscal year end?
December 31st
Who are Hepion’s independent auditors?
Hepion’s auditors are BDO USA, LLP.
Who is Hepion’s outside legal counsel?
Hepion’s outside legal counsel is Jeffrey J. Fessler, a partner in the Corporate Practice at Sheppard Mullin in New York, NY.